# Payers pre-commit to cover off-label generics when a definitive trial is positive

Source: https://onco.cc/ideas/idea-reg-payer-coverage-off-label-generic-commitment/  
OnCo record `idea-reg-payer-coverage-off-label-generic-commitment` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Even when a trial proves a cheap old drug helps, insurers may refuse to pay because it is not licensed for cancer. A standing promise to pay would remove that fear.

## Summary

Uncertainty about reimbursement discourages trialists and clinicians and leaves proven repurposed treatments unused. The proposal is a formal coverage policy, adopted by public payers and large insurers, stating that any off-patent drug shown in a registration-quality randomised trial to improve survival or a validated patient-relevant endpoint in cancer will be covered for that use within six months of publication, subject to an independent evidence review, regardless of label status. The policy is published in advance so trial funders can rely on it.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Payers adopting the policy see faster uptake of proven repurposed interventions and the policy is cited by funders as a reason for funding new repurposing trials.
- Rationale: Coverage is the endpoint that matters for a generic drug; guaranteeing it in advance turns a speculative trial into a fundable one and removes the last excuse for non-use after a positive result.
- Proposed test: Adopt the policy in two public payers; measure time from publication to coverage for the next positive repurposing trials and survey funders about its influence.
- Maturity: speculative
- Actor: payer

## Sources

- Bottleneck evidence (No incentive to repurpose cheap drugs): Pantziarka et al., The Repurposing Drugs in Oncology (ReDO) Project (ecancer 2014): https://doi.org/10.3332/ecancer.2014.442

## Connected records

- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/)
- key papers: [The Repurposing Drugs in Oncology (ReDO) Project](https://onco.cc/key-papers/paper-pantziarka-ecancermedicalscience/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-payer-coverage-off-label-generic-commitment.json